State of the Art Symposium: prescreening and rescreening.
The effectiveness of prescreening and rescreening cervical cytology preparations-whether used as quality assurance measures or in the attempt to improve sensitivity-has engendered broad discussion within the cytology community. This paper forms an introduction to some of the issues surrounding prescreening and rescreening in cervical cytology.
O'Leary
Timothy J
TJ
Department of Cellular Pathology and Genetics, Armed Forces Institute of Pathology, Washington, DC, USA. timothy.oleary@hq.med.va.gov
D001331:Automation; D003362:Cost-Benefit Analysis; D005260:Female; D006291:Health Policy; D006801:Humans; D008403:Mass Screening; D011785:Quality Assurance, Health Care; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis*; D014626:Vaginal Smears / Q000191:economics